Anzeige
Meldung des Tages: China-Monopol wackelt: Wird Western Star Resources zur politisch gewollten Wolfram-Lösung der USA?

Cambiar Aggressive Value ETF News

ETF
WKN:  ISIN:  US0075W01639 US-Symbol:  CAMX
26,188 €
+0,00 $
0,00%
26,188 € 27.03.26
Depot/Watchlist
Indexbildung
Ertragsverwendung
-
Lfd. Kosten
-
Fondsgröße
-  
Tracking Error
-
Währung
FWW Fundstars
keine Bewertung

Cambiar Aggressive Value ETF News

11:34 Uhr - PR Newswire
Camurus announces expansion of Lilly collaboration
Camurus announces expansion of Lilly collaboration PR Newswire
11:33 Uhr - PR Newswire
Camurus announces expansion of Lilly collaboration
Camurus announces expansion of Lilly collaboration PR Newswire
09.01.26 - PR Newswire
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly PR Newswire
09.01.26 - PR Newswire
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly PR Newswire
10.11.25 - PR Newswire
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
Camurus reports positive topline results for CAM2056, semaglutide monthly depot PR Newswire
10.11.25 - PR Newswire
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
Camurus reports positive topline results for CAM2056, semaglutide monthly depot PR Newswire
28.08.25 - PR Newswire
Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK
Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK PR Newswire
01.07.25 - PR Newswire
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU PR Newswire
01.07.25 - PR Newswire
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU PR Newswire
18.06.25 - PR Newswire
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients PR Newswire
18.06.25 - PR Newswire
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients PR Newswire
03.06.25 - PR Newswire
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Camurus and Lilly enter collaboration and license agreement for long-​acting FluidCrystal® incretins PR Newswire
03.06.25 - PR Newswire
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Camurus and Lilly enter collaboration and license agreement for long-​acting FluidCrystal® incretins PR Newswire

Newssuche

Videos

newspaper
29.05.26 -5,61%
Technical Trading: Kurzfrist Signal im Goldpreis
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »